抑制白细胞介素-1受体相关激酶1是急性髓系白血病亚型的治疗策略
IRAK1在急性髓系白血病(AML)中过表达并为白血病细胞提供生存信号,遗传敲低可显著降低白血病负荷。多激酶抑制剂帕瑞替尼对IRAK1有强抑制活性,可抑制多种遗传异常AML细胞生长并减少白血病祖细胞和小鼠模型中的白血病负荷。
要点
- IRAK1在AML中过表达,为AML细胞提供生存信号。
- 帕瑞替尼对IRAK1有强抑制活性,可降低AML细胞IRAK1磷酸化。
- 帕瑞替尼抑制多种遗传异常AML细胞生长并减少白血病负荷。
核心结论
- IRAK1参与白血病细胞生存,抑制IRAK1可能对异质性AML亚型有益。
研究设计与样本
- 研究评估IRAK1在AML中的作用及多激酶抑制剂帕瑞替尼对IRAK1的抑制活性。
主要发现
- IRAK1在AML中过表达并为AML细胞提供生存信号。
- 在原代AML样本和异种移植模型中遗传敲低IRAK1显示白血病负荷显著降低。
- 激酶谱分析表明帕瑞替尼对IRAK1有强抑制活性,计算建模结合定点诱变显示帕瑞替尼与IRAK1激酶域高亲和力结合。
- 帕瑞替尼暴露降低AML细胞中IRAK1磷酸化。
- 较高比例的原代AML样本对帕瑞替尼(抑制FLT3、JAK2和IRAK1)表现出稳健敏感性,相对于FLT3抑制剂quizartinib或JAK1/2抑制剂ruxolitinib,证明IRAK1抑制的重要性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interleukin-1 receptor-associated kinase 1 (IRAK1), an essential mediator of innate immunity and inflammatory responses, is constitutively active in multiple cancers. We evaluated the role of IRAK1 in acute myeloid leukemia (AML) and assessed the inhibitory activity of multikinase inhibitor pacritinib on IRAK1 in AML. We demonstrated that IRAK1 is overexpressed in AML and provides a survival signal to AML cells. Genetic knockdown of IRAK1 in primary AML samples and xenograft model showed a significant reduction in leukemia burden. Kinase profiling indicated pacritinib has potent inhibitory activity against IRAK1. Computational modeling combined with site-directed mutagenesis demonstrated high-affinity binding of pacritinib to the IRAK1 kinase domain. Pacritinib exposure reduced IRAK1 phosphorylation in AML cells. A higher percentage of primary AML samples showed robust sensitivity to pacritinib, which inhibits FLT3, JAK2, and IRAK1, relative to FLT3 inhibitor quizartinib or JAK1/2 inhibitor ruxolitinib, demonstrating the importance of IRAK1 inhibition. Pacritinib inhibited the growth of AML cells harboring a variety of genetic abnormalities not limited to FLT3 and JAK2. Pacritinib treatment reduced AML progenitors in vitro and the leukemia burden in AML xenograft model. Overall, IRAK1 contributes to the survival of leukemic cells, and the suppression of IRAK1 may be beneficial among heterogeneous AML subtypes.
引用
- Hosseini MM, Kurtz SE, Abdelhamed S, et al. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia. 2018. PMID: 29743719. doi:10.1038/s41375-018-0112-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。